GlassScriptPhysician profile
Zuleika Font
NPI 1760483945
$6,754.62
in general payments reported to CMS, 2019-2025
35 companies · $1,585 in 2025
The $1,585 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,958 · 2020: $301 · 2021: $11.97 · 2022: $51.31 · 2023: $946 · 2024: $1,901 · 2025: $1,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,431.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $985.92 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $902.82 | 2019-2025 | |
| Abbvie INC. | $845.78 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $510.72 | 2019-2025 | Farxiga, Airsupra |
| Astellas Pharma US INC | $496.48 | 2019-2025 | Veozah |
| Lilly USA, LLC | $426.52 | 2019-2025 | Mounjaro, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.84 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $297.26 | 2019-2025 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $244.69 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $193.46 | 2019-2025 | Eliquis, Camzyos |
| Insulet Corporation | $179.58 | 2025 | Omnipod |
| Inspire Medical Systems, INC. | $144.88 | 2023-2025 | Inspire |
| Gilead Sciences, INC. | $133.59 | 2019-2025 | |
| Glaxosmithkline, LLC. | $118.92 | 2019-2025 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.59 | 2019-2025 | Xifaxan |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $111.11 | 2019-2025 | |
| Eisai INC. | $83.91 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $72.98 | 2019-2025 | |
| Inari Medical, INC. | $64.43 | 2024-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Exact Sciences Corporation | $50.41 | 2023-2024 | Cologuard Collection Kit |
| Radius Health, INC. | $50.34 | 2019 | |
| Sanofi Pasteur INC. | $42.31 | 2019 | |
| Merck Sharp & Dohme LLC | $42.06 | 2019 | |
| Allergan, INC. | $39.67 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.43 | 2022 | |
| Janssen Pharmaceuticals, INC | $37.98 | 2019 | |
| Shire North American Group INC | $35.42 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.14 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $29.86 | 2024 | Abilify Mycite |
| Viiv Healthcare Company | $28.77 | 2024 | Apretude |
| Boston Scientific Corporation | $26.30 | 2024 | Bodyguardian |
| Circassia INC. | $14.46 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.03 | 2019 | |
| Esperion Therapeutics, INC. | $13.18 | 2024 | Nexletol |
| Seqirus USA INC | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zuleika Font listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.